JPRN-UMIN000000929CompletedPhase 2
Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma (JCOG0601) - Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma (JCOG0601)
Japan Clinical Oncology Group(JCOG)0 sites422 target enrollmentStarted: December 4, 2007Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 422
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 79years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1)anamnesis of graucoma (2)diabetes mellitus treating insulin or uncontrolled (3)uncontrollable hypertension (4)coronary artery necessary, cardiomyopathy and heart failure necessary treatment, arrhythmia treating antiarrhyshmic (5)HBs-Ag positive (6)HCV positive (7)HIV positive (8)interstitial pneumonia, plumonary fiblosis (9)severe infection (10)synchronous or metachronous malignancy (11)pregnant/lactating woman (12)psychosis (13)given systemic steroid
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma - N/AFirst-Line Diffuse Large B-Cell LymphomaMedDRA version: 9.1Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)EUCTR2008-005496-10-IEEli Lilly and Company100
Active, not recruiting
Phase 1
Randomized phase II study of treatment with R-CHOP vs Bortezomib-R-CAP for young patients with poor IPI diffuse large B-cell lymphoma.EUCTR2012-005138-12-ESGELTAMO (Grupo Cooperativo Español de Linfoma/Trasplante Autólogo de Médula Ósea)127
Completed
Phase 2
Randomized phase II study of biweekly R-CHOP versus biweekly R-CHOP followed by CHASER as induction therapy for high-dose chemotherapy, LEED, and autologous stem-cell transplantation in poor-risk diffuse large B-cell lymphoma (JCOG0908, DLBCL-bi-R-CHOP/CHASER-LEED-rP2 )diffuse large B-cell lymphoma, including subtypeslymphomatoid granulomatosis, grade 3primary mediastinal (thymic) large B-cell lymphomaJPRN-UMIN000003823Japan Clinical Oncology Group (JCOG)70
Active, not recruiting
Phase 1
A trial of CHOP-R therapy with or without acalabrutinib in patients with newly diagnosed Richter's SyndromeEUCTR2017-004401-40-GBniversity of Birmingham105
Active, not recruiting
Not Applicable
A phase II study of R-CHOP with intensive CNS prophylaxis and scrotal irradiation in patients with primary testicular diffuse large B-cell lymphoma - IELSG30EUCTR2009-011789-26-ITIELSG-International Extranodal Lymphoma Study Group35